Clinical Pipeline

Below is our pipeline of investigational compounds that are currently in various stages of clinical development.

Phase 1	Phase 2	Phase 3

DNMT inhibitor (Hematological Malignancies and Solid Tumors)

DNMT inhibitor (Treatment Naïve AML)

.	.	.

DNMT inhibitor (Relapsed/Refractory AML)

.	.	.

DNMT inhibitor (Relapsed/Refractory MDS or CMML)

.	.	.

DNMT inhibitor (Solid Tumors)

.	.

Oral DNMT inhibitor (Hematological Malignancies)

.	.	.

Dual IAP Antagonist (Solid Tumors & Lymphomas)

.	.

Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)

.

Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)

.